ABL News

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

ABL’s collaborative partnering approach coupled with Just – Evotec Biologics’ development capabilities will enable the delivery of clinical materials by the end of 2020.
June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

ABL announces the hire of Jarlath Keating as Chief Commercial Officer.  As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL. 

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.

May 16, 2016

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) –ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand–

March 11, 2016

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.

March 3, 2016

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

February 18, 2016

ABL, Inc. Launches Virus Manufacturing Operations in Europe

Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.

February 3, 2016

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

January 14, 2016

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

July 10, 2015

ABL Named Small Business Champion by Montgomery County

Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.

June 30, 2015

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).

March 24, 2015

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).

February 13, 2015

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

Rockville, MD – February 13, 2015 – The release of Novavax’s Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal’s Spring 2015 article “Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology” (BioProcessing Journal, Hahn, Timothy, et al.).

January 20, 2015

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.

August 18, 2014

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.

July 21, 2014

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

March 4, 2014

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.

January 24, 2014

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.

December 24, 2013

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.

November 6, 2013

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

October 30, 2013

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

October 1, 2013

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.

June 19, 2013

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.

June 12, 2013

ABL To Attend Biodefense Vaccines and Therapeutics Summit

ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.

June 4, 2013

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

May 1, 2013

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).

April 11, 2013

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

March 29, 2013

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

February 19, 2013

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

January 8, 2013

ABL 2012 Publications and Presentations

In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.

November 6, 2012

ABL Announces Additions to Manufacturing and Quality Control Teams

Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

August 1, 2012

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.

July 25, 2012

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide “Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases.”

June 12, 2012

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.

February 14, 2012

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

Ann Arbor, MI and Rockville, MD [February 14, 2012] – AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.

February 8, 2012

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

January 10, 2012

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

November 14, 2011

ABL Launches New Website

Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.

September 14, 2011

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.

August 28, 2011

ABL Completes Validation of New cGMP Manufacturing Facility

ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.

June 20, 2011

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

Rockville, MD (July 20, 2011) – Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy.”

June 6, 2011

Contract Pharma: ABL Opens Newly Expanded HQ

Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.

June 5, 2011

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.

June 3, 2011

BioWatch: ABL Turns 50 with New Digs, Open House

Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.

March 30, 2011

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

Rockville, MD (March 30, 2011) – Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.

January 6, 2011

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

Kensington, MD (January 6, 2011) – Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

ABL announces the hire of Jarlath Keating as Chief Commercial Officer.  As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL. 

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.

May 16, 2016

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) –ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand–

March 11, 2016

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.

March 3, 2016

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

February 18, 2016

ABL, Inc. Launches Virus Manufacturing Operations in Europe

Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.

February 3, 2016

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

January 14, 2016

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

July 10, 2015

ABL Named Small Business Champion by Montgomery County

Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.

June 30, 2015

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).

March 24, 2015

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).

February 13, 2015

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

Rockville, MD – February 13, 2015 – The release of Novavax’s Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal’s Spring 2015 article “Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology” (BioProcessing Journal, Hahn, Timothy, et al.).

January 20, 2015

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.

August 18, 2014

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.

July 21, 2014

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

March 4, 2014

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.

January 24, 2014

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.

December 24, 2013

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.

November 6, 2013

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

October 30, 2013

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

October 1, 2013

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.

June 19, 2013

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.

June 12, 2013

ABL To Attend Biodefense Vaccines and Therapeutics Summit

ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.

June 4, 2013

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

May 1, 2013

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).

April 11, 2013

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

March 29, 2013

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

February 19, 2013

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

January 8, 2013

ABL 2012 Publications and Presentations

In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.

November 6, 2012

ABL Announces Additions to Manufacturing and Quality Control Teams

Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

August 1, 2012

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.

July 25, 2012

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide “Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases.”

June 12, 2012

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.

February 14, 2012

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

Ann Arbor, MI and Rockville, MD [February 14, 2012] – AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.

February 8, 2012

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

January 10, 2012

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

November 14, 2011

ABL Launches New Website

Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.

September 14, 2011

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.

August 28, 2011

ABL Completes Validation of New cGMP Manufacturing Facility

ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.

June 20, 2011

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

Rockville, MD (July 20, 2011) – Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy.”

June 6, 2011

Contract Pharma: ABL Opens Newly Expanded HQ

Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.

June 5, 2011

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.

June 3, 2011

BioWatch: ABL Turns 50 with New Digs, Open House

Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.

March 30, 2011

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

Rockville, MD (March 30, 2011) – Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.

January 6, 2011

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

Kensington, MD (January 6, 2011) – Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

ABL announces the hire of Jarlath Keating as Chief Commercial Officer.  As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL. 

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.

May 16, 2016

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) –ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand–

March 11, 2016

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.

March 3, 2016

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

February 18, 2016

ABL, Inc. Launches Virus Manufacturing Operations in Europe

Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.

February 3, 2016

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

January 14, 2016

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

July 10, 2015

ABL Named Small Business Champion by Montgomery County

Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.

June 30, 2015

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).

March 24, 2015

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).

February 13, 2015

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

Rockville, MD – February 13, 2015 – The release of Novavax’s Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal’s Spring 2015 article “Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology” (BioProcessing Journal, Hahn, Timothy, et al.).

January 20, 2015

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.

August 18, 2014

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.

July 21, 2014

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

March 4, 2014

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.

January 24, 2014

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.

December 24, 2013

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.

November 6, 2013

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

October 30, 2013

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

October 1, 2013

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.

June 19, 2013

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.

June 12, 2013

ABL To Attend Biodefense Vaccines and Therapeutics Summit

ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.

June 4, 2013

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

May 1, 2013

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).

April 11, 2013

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

March 29, 2013

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

February 19, 2013

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

January 8, 2013

ABL 2012 Publications and Presentations

In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.

November 6, 2012

ABL Announces Additions to Manufacturing and Quality Control Teams

Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

August 1, 2012

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.

July 25, 2012

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide “Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases.”

June 12, 2012

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.

February 14, 2012

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

Ann Arbor, MI and Rockville, MD [February 14, 2012] – AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.

February 8, 2012

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

January 10, 2012

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

November 14, 2011

ABL Launches New Website

Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.

September 14, 2011

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.

August 28, 2011

ABL Completes Validation of New cGMP Manufacturing Facility

ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.

June 20, 2011

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

Rockville, MD (July 20, 2011) – Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy.”

June 6, 2011

Contract Pharma: ABL Opens Newly Expanded HQ

Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.

June 5, 2011

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.

June 3, 2011

BioWatch: ABL Turns 50 with New Digs, Open House

Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.

March 30, 2011

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

Rockville, MD (March 30, 2011) – Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.

January 6, 2011

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

Kensington, MD (January 6, 2011) – Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

ABL announces the hire of Jarlath Keating as Chief Commercial Officer.  As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL. 

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.

May 16, 2016

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) –ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand–

March 11, 2016

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.

March 3, 2016

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

February 18, 2016

ABL, Inc. Launches Virus Manufacturing Operations in Europe

Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.

February 3, 2016

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

January 14, 2016

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

July 10, 2015

ABL Named Small Business Champion by Montgomery County

Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.

June 30, 2015

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).

March 24, 2015

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).

February 13, 2015

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

Rockville, MD – February 13, 2015 – The release of Novavax’s Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal’s Spring 2015 article “Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology” (BioProcessing Journal, Hahn, Timothy, et al.).

January 20, 2015

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.

August 18, 2014

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.

July 21, 2014

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

March 4, 2014

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.

January 24, 2014

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.

December 24, 2013

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.

November 6, 2013

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

October 30, 2013

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

October 1, 2013

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.

June 19, 2013

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.

June 12, 2013

ABL To Attend Biodefense Vaccines and Therapeutics Summit

ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.

June 4, 2013

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

May 1, 2013

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).

April 11, 2013

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

March 29, 2013

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

February 19, 2013

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

January 8, 2013

ABL 2012 Publications and Presentations

In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.

November 6, 2012

ABL Announces Additions to Manufacturing and Quality Control Teams

Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

August 1, 2012

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.

July 25, 2012

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide “Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases.”

June 12, 2012

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.

February 14, 2012

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

Ann Arbor, MI and Rockville, MD [February 14, 2012] – AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.

February 8, 2012

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

January 10, 2012

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

November 14, 2011

ABL Launches New Website

Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.

September 14, 2011

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.

August 28, 2011

ABL Completes Validation of New cGMP Manufacturing Facility

ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.

June 20, 2011

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

Rockville, MD (July 20, 2011) – Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy.”

June 6, 2011

Contract Pharma: ABL Opens Newly Expanded HQ

Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.

June 5, 2011

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.

June 3, 2011

BioWatch: ABL Turns 50 with New Digs, Open House

Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.

March 30, 2011

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

Rockville, MD (March 30, 2011) – Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.

January 6, 2011

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

Kensington, MD (January 6, 2011) – Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

ABL announces the hire of Jarlath Keating as Chief Commercial Officer.  As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL. 

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.